Reducing the osteoporosis treatment gap: an interview with UCB's Pascale Richetta

Dr. Pascale Richetta is Executive Vice President and Head of the Bone Patient Value Unit at UCB (Brussels, Belgium). She joined UCB in 2016 following over 20 years’ experience in the pharma and biotech industry. After completing her MD at the University of Poitiers (France), she spent time as vice p...

Descripción completa

Detalles Bibliográficos
Autor principal: Richetta, Pascale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2017
Materias:
Interview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778375/
https://www.ncbi.nlm.nih.gov/pubmed/29379635
http://dx.doi.org/10.4155/fsoa-2017-0110
_version_ 1783294341506138112
author Richetta, Pascale
author_facet Richetta, Pascale
author_sort Richetta, Pascale
collection PubMed
description Dr. Pascale Richetta is Executive Vice President and Head of the Bone Patient Value Unit at UCB (Brussels, Belgium). She joined UCB in 2016 following over 20 years’ experience in the pharma and biotech industry. After completing her MD at the University of Poitiers (France), she spent time as vice president at Abbvie/Abbott and has also held positions at GlaxoSmithKline, Ipsen and Servier. Through the course of her career she acquired impressive commercial experience managing both traditional pharmaceuticals and complex biologics and her knowledge of markets around the world is key to helping UCB prepare for future product launches.
format Online
Article
Text
id pubmed-5778375
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Future Science Ltd
record_format MEDLINE/PubMed
spelling pubmed-57783752018-01-29 Reducing the osteoporosis treatment gap: an interview with UCB's Pascale Richetta Richetta, Pascale Future Sci OA Interview Dr. Pascale Richetta is Executive Vice President and Head of the Bone Patient Value Unit at UCB (Brussels, Belgium). She joined UCB in 2016 following over 20 years’ experience in the pharma and biotech industry. After completing her MD at the University of Poitiers (France), she spent time as vice president at Abbvie/Abbott and has also held positions at GlaxoSmithKline, Ipsen and Servier. Through the course of her career she acquired impressive commercial experience managing both traditional pharmaceuticals and complex biologics and her knowledge of markets around the world is key to helping UCB prepare for future product launches. Future Science Ltd 2017-11-22 /pmc/articles/PMC5778375/ /pubmed/29379635 http://dx.doi.org/10.4155/fsoa-2017-0110 Text en © 2017 Dr Pascale Richetta This work is licensed under a Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/)
spellingShingle Interview
Richetta, Pascale
Reducing the osteoporosis treatment gap: an interview with UCB's Pascale Richetta
title Reducing the osteoporosis treatment gap: an interview with UCB's Pascale Richetta
title_full Reducing the osteoporosis treatment gap: an interview with UCB's Pascale Richetta
title_fullStr Reducing the osteoporosis treatment gap: an interview with UCB's Pascale Richetta
title_full_unstemmed Reducing the osteoporosis treatment gap: an interview with UCB's Pascale Richetta
title_short Reducing the osteoporosis treatment gap: an interview with UCB's Pascale Richetta
title_sort reducing the osteoporosis treatment gap: an interview with ucb's pascale richetta
topic Interview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778375/
https://www.ncbi.nlm.nih.gov/pubmed/29379635
http://dx.doi.org/10.4155/fsoa-2017-0110
work_keys_str_mv AT richettapascale reducingtheosteoporosistreatmentgapaninterviewwithucbspascalerichetta

Ejemplares similares